Mizuho analyst Graig Suvannavejh raised the firm’s price target on Insmed (INSM) to $256 from $196 and keeps an Outperform rating on the shares. The firm increased estimates across the company’s three key assets: Arikayce, Brinsupri, and Treprostinil Palmitil Inhalation Powder. As many as three clinical catalysts in the first half of 2026 “could propel the stock even higher,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $231 from $223 at TD Cowen
- Insmed’s Brinsupri Approval and Strategic Market Expansion Justify Buy Rating
- Insmed’s BRINSUPRI Approved by European Commission
- Insmed’s Brinsupri approved in EU for non-cystic fibrosis bronchiectasis
- Insmed price target raised to $225 from $196 at Goldman Sachs